Novo Nordisk Licenses Experimental Once-Weekly Obesity Pill From China's Hengrui in Deal Worth Up to $2.6 Billion Medical Daily 3d
Could this company challenge Eli Lilly and Novo Nordisk in the weight loss market? The Motley Fool 4d Tirzepatide Mounjaro Health & Fitness All sources
Novo outlays $2.6bn in Hengrui deal to bolster oral obesity pipeline Pharmaceutical Technology 5d Hengrui Obesity China All sources
Eli Lilly obesity drug data adds pressure on Novo Nordisk Proactive Investors (US) 2d Obesity Tirzepatide Mounjaro
Novo Nordisk licenses experimental once-weekly obesity pill from China's Hengrui in deal worth up to $2.6 Billion Medical Daily 3d Mounjaro Obesity China All sources
